Could this Healthcare Stock really climb 988.61% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( This email is part of your free subscription for subscriber: {EMAIL} You can unsubscribe at any time. --------------------------------------------------------------- Sponsor Message [Americans Now Favor Gold Over Stocks as an Investment Vehicle]( [See why investors are so impressed by this overlooked gold investment strategy.]( --------------------------------------------------------------- February 14, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- [Agnico Eagle Mines Limited]( Symbol: [AEM]( Recent Price: $44.98 Average Analyst Price Target: $65.04 (44.60%) Market Cap: $22.24B Last Year's EPS: $0.65 Consensus EPS Forecast: $0.46 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Mike Parkin, analyst at National Bank, reiterates coverage on [Agnico Eagle Mines Limited (AEM)]( in the Basic Materials sector with a Buy rating and a price target of $61.92 (1 week ago). [TipRanks.com]( also reports that [Agnico Eagle Mines Limited]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $65.04 . The target pricing ranges from a high forecast of $71 down to a low forecast of $61. [Agnico Eagle Mines Limited (AEM)](’s last closing price was $44.98 which would put the average price target at 44.60% upside. Here are 3rd party ratings for [AEM](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 28% (181 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Ultragenyx Pharmaceutical Inc.]( Symbol: [RARE]( Recent Price: $43.98 Average Analyst Price Target: $79.75 (81.33%) Market Cap: $3.61B Last Year's EPS: $-2.25 Consensus EPS Forecast: $-2.08 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Whitney Ijem, analyst at Canaccord Genuity, reiterates coverage on [Ultragenyx Pharmaceutical Inc. (RARE)]( in the Healthcare sector with a Buy rating and a price target of $110 (1 week ago). [TipRanks.com]( also reports that [Ultragenyx Pharmaceutical Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $79.75 . The target pricing ranges from a high forecast of $82 down to a low forecast of $110. [Ultragenyx Pharmaceutical Inc. (RARE)](’s last closing price was $43.98 which would put the average price target at 81.33% upside. Here are 3rd party ratings for [RARE](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Pacific Biosciences of California, Inc.]( Symbol: [PACB]( Recent Price: $6.08 Average Analyst Price Target: $13.10 (115.46%) Market Cap: $1.63B Last Year's EPS: $-0.26 Consensus EPS Forecast: $-0.3 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Daniel Brennan, analyst at TD Cowen, reiterates coverage on [Pacific Biosciences of California, Inc. (PACB)]( in the Healthcare sector with a Buy rating and a price target of $19 (2 days ago). [TipRanks.com]( also reports that [Pacific Biosciences of California, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $13.10 . The target pricing ranges from a high forecast of $8 down to a low forecast of $11. [Pacific Biosciences of California, Inc. (PACB)](’s last closing price was $6.08 which would put the average price target at 115.46% upside. Here are 3rd party ratings for [PACB](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 42% (106 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [URGENT: Don't risk your retirement]( looming recession, inflation, unpayable debt, a failing dollar, and a crumbling housing market all put your savings in extreme risk. Protect your retirement with this free guide that shows you how to guard your money against economic downturns with gold. Take action NOW, before it’s too late, Download your free guide and see for yourself why gold is the #1 safe haven for smart investors. [Protect your retirement with this free gold guide]( --------------------------------------------------------------- [Prothena Corporation plc]( Symbol: [PRTA]( Recent Price: $26.49 Average Analyst Price Target: $69.00 (160.48%) Market Cap: $1.42B Last Year's EPS: $-1.03 Consensus EPS Forecast: $-0.32 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Tazeen Ahmad, analyst at Bank of America Securities, reiterates coverage on [Prothena Corporation plc (PRTA)]( in the Healthcare sector with a Hold rating and a price target of $38 (2 weeks ago). [TipRanks.com]( also reports that [Prothena Corporation plc]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $69.00 . The target pricing ranges from a high forecast of $94 down to a low forecast of $36. [Prothena Corporation plc (PRTA)](’s last closing price was $26.49 which would put the average price target at 160.48% upside. Here are 3rd party ratings for [PRTA](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [AtriCure, Inc.]( Symbol: [ATRC]( Recent Price: $31.71 Average Analyst Price Target: $55.60 (75.34%) Market Cap: $1.50B Last Year's EPS: $-0.12 Consensus EPS Forecast: $-0.3 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Danielle Antalffy, analyst at UBS, reiterates coverage on [AtriCure, Inc. (ATRC)]( in the Healthcare sector with a Buy rating and a price target of $57 (3 weeks ago). [TipRanks.com]( also reports that [AtriCure, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $55.60 . The target pricing ranges from a high forecast of $65 down to a low forecast of $44. [AtriCure, Inc. (ATRC)](’s last closing price was $31.71 which would put the average price target at 75.34% upside. Here are 3rd party ratings for [ATRC](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 35% (162 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Richest investors clearly worried about something big]( Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5.) [Click for full story.]( --------------------------------------------------------------- [Palatin Technologies, Inc.]( Symbol: [PTN]( Recent Price: $3.95 Average Analyst Price Target: $43.00 (988.61%) Market Cap: $63.74M Last Year's EPS: $-0.91 Consensus EPS Forecast: $-0.75 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Palatin Technologies, Inc. (PTN)]( in the Healthcare sector with a Buy rating and a price target of $70 (1 month ago). [TipRanks.com]( also reports that [Palatin Technologies, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $43.00 . The target pricing ranges from a high forecast of $9 down to a low forecast of $50. [Palatin Technologies, Inc. (PTN)](’s last closing price was $3.95 which would put the average price target at 988.61% upside. Here are 3rd party ratings for [PTN](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 36% (89 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Karyopharm Therapeutics Inc.]( Symbol: [KPTI]( Recent Price: $1.29 Average Analyst Price Target: $5.75 (345.74%) Market Cap: $147.18M Last Year's EPS: $-0.29 Consensus EPS Forecast: $-0.28 Expected Earnings Date: Feb 15, 2024 Recent Analyst Action: Brian Abrahams, analyst at RBC Capital, reiterates coverage on [Karyopharm Therapeutics Inc. (KPTI)]( in the Healthcare sector with a Buy rating and a price target of $3 (1 week ago). [TipRanks.com]( also reports that [Karyopharm Therapeutics Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.75 . The target pricing ranges from a high forecast of $5 down to a low forecast of $10. [Karyopharm Therapeutics Inc. (KPTI)](’s last closing price was $1.29 which would put the average price target at 345.74% upside. Here are 3rd party ratings for [KPTI](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 38% (96 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Strategic Gold Play You Haven't Heard About]( recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. [Get the full story on this overlooked gold investment strategy here.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, DailyTickerPress.com DailyTickerPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to DailyTickerPress.com [If you are not a human, click here.]( Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software